The UPMC Presbyterian Shadyside PGY1 pharmacy residency programs build on Doctor of Pharmacy (PharmD) education and outcomes to contribute to the development of clinical pharmacists responsible for medication-related care of patients with a wide range of conditions, eligible for board certification, and eligible for postgraduate year two (PGY2) pharmacy residency training.
Graduates of our program are poised for success as:
Patient care providers
Our educational outcomes include:
Provide safe and effective patient care
Advance Pharmacy Practice and Improve Patient
Demonstrate leadership in pharmacy practice
Care Manage and improve the medication-use process
Provide medication and practice-related education/training
Contribute to formulary decisions
The goal of the residency program is that highly motivated pharmacists will have the knowledge, skills, abilities, and attitudes necessary to independently and competently optimize pharmacotherapy outcomes through their direct involvement in patient care as well as pharmacy practice management
All residents must be eligible for pharmacist licensure in the Commonwealth of Pennsylvania. Applications for Pharmacist License and Intern Registration are available.
Pennsylvania requires 1500 registered intern hours in order to be eligible for licensure. Of the 1500 hours, only 1000 hours can be obtained through an academic program. That is, 500 intern hours must be obtained outside of school. These 1500 intern hours must be registered with a state board of pharmacy to count toward licensure in Pennsylvania. If you have not yet started registering hours with your state board of pharmacy, we encourage you to do so as soon as possible in order to be eligible for Pennsylvania licensure. We also encourage you to review your own state's rules regarding the registration, reporting and transfer of intern hours. Please do not hesitate to discuss any questions you have regarding licensure with individual program directors.
Eligible candidates will be graduating or have graduated from an accredited school of pharmacy. Candidates must register for the Match – ASHP Residency Matching Program and submit application requirements via PhORCAS by December 31st. Select candidates will be invited for an on-site interview, which are typically conducted during the month of February. An on-site interview is required. Applicants not selected for an on-site interview will be notified by February 1.
We request that at least one (preferably two) of the three references come from a preceptor with whom you have worked in a clinical setting. The preceptor should be able to comment on your responsibilities, patient load, clinical problem solving as well as time management. All reference writers must use the standard PHORCAS template and provide comments on a minimum of 7 of the 13 characteristics in the spaces provided.
This residency site agrees that no person at this site will solicit, accept, or use any ranking related information from any residency candidate.
PGY1 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and outcomes to contribute to the development of clinical pharmacists responsible for medication-related care of patients with a wide range of conditions, eligible for board certification, and eligible for postgraduate year two (PGY2) pharmacy resident training.
To prepare pharmacists to assume any of the following roles:
Patient care provider;
PGY2 training in their specialty area of choice;
Our residents will become confident, effective practitioners of pharmacotherapy. Residents will focus on ensuring application of safe, effective and evidence-based medicine practices to individual patients and in populations across the health system. These practitioners will demonstrate competency in educating their patients as well as present and future health care professionals.
Duration: 12 months
Number Positions: 4
Starting Date: July 1
Vacation: 10 days paid leave
Travel Stipend: The amount is determined yearly and may not cover all travel expenses.
Insurance: Health, dental, eye care, life, and disability available, Vacation and professional travel provided,
Training Site Type: UPMC Presbyterian
The direct patient care series provides at least one 5-week experience in internal medicine and critical care. The third 5-week experience is precepting in one of these areas.
Other elective rotations are available based on resident interest and preceptor availability.
Brian Baum, PharmD BCPS
James Coons, PharmD BCPS, AQ(CV)
Lara Groetzinger, PharmD BCCCP
Ashleigh Hogue, PharmD BCCCP
Heather J. Johnson, PharmD BCPS (Director)
Catherine Kim, PharmD BCPS, BCCCP
Alfred L’Altrelli, PharmD
Taylor Miller, PharmD
Van Nguyen, PharmD BCPS
Ryan Rivosecchi, PharmD BCCP
Eric Schafer, PharmD
Kristen Shimko, PharmD
Janine Then, PharmD
Cory Weaver, PharmD BCCCP
Iasella CJ, Johnson HJ, Dunn MA. Adverse Drug Reactions: Type A (Intrinsic) or Type B (Idiosyncratic). Clinics in Liver Disease 2017;21:73-87.
Rivosecchi RM, Kane-Gill, SL, Garavaglia J, MacLasco A, Johnson HJ. The effectiveness of intravenous vitamin K in correcting cirrhosis-associated coagulopathy. International Journal of Pharmacy Practice. 2017 doi:10.1111/ijpp.12355
Smith MA; Hibino M; Falcione BA; Eichinger KM; Patel R; Empey KM. Immunosuppressive aspects of analgesics and sedatives used in mechanically ventilated patients: an underappreciated risk factor for the development of ventilator-associated pneumonia in critically ill patients.Annals of Pharmacotherapy. 48(1):77-85, 2014 Jan
Bremmer DN , Clancy CJ , Press EG , Almaghrabi R, Chen L, Doi Y, Nguyen MH, and . Shields RK. KPC-Producing Klebsiella pneumoniae Strains That Harbor AAC(6′)-Ib Exhibit Intermediate Resistance to Amikacin Antimicrob. Agents Chemother. December 2014 58:7597-7600; published ahead of print 6 October 2014, doi:10.1128/AAC.03831-14
Sales I; Jonkman L; Connor S; Hall D. A comparison of educational interventions to enhance cultural competency in pharmacy students. American Journal of Pharmaceutical Education. 77(4):76, 2013 May 13
Jernigan MG; Press EG; Nguyen MH; Clancy CJ; Shields RK The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrobial Agents & Chemotherapy. 56(6):3395-8, 2012 Jun.
Duesenberry CM, Coley KC, Kortykowski MT, Donihi AC. Hypoglycemia in hospitalized patient treated with sulfonylureas. Pharmacotherapy 2012:32:613-617.
Schonder KS. Corman SL. Hung WY. Early risk factors for persistent anemia after kidney transplantation. Pharmacotherapy 30(12):1214-20, 2010 Dec.
Smithburger PL. Seybert AL. Armahizer MJ. Kane-Gill SL. QT prolongation in the intensive care unit: commonly used medicatiosn and the impact of drug-drug interactions. [Review] Expert Opinion on Drug Safety. 9(5):699-712, 2010 Sep.
Lavsa SM. Fabian TJ. Saul MI. Corman SL. Coley KC. Influence of medications and diagnoses on fall risk in psychiatric inpatients. American Journal of Health-System Pharmacy. 67(15):1274-80, 2010 Aug.
Martello JL. Pummer TL. Krenzelok EP. Cost minimization analysis comparing enteral N-acetylcysteine to intravenous acetylcysteine in the management of acute acetaminophen toxicity. Clinical Toxicology: The Official Journal of the American Academy of Clinical Toxicology & European Association of Poisons Centres & Clinical Toxicologists. 48(1):79-83, 2010 Jan.
Havrilla PL. Kane-Gill SL. Verrico MM. Seybert AL. Reis SE. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Annals of Pharmacotherapy. 43(3):532-6, 2009 Mar.
Pogue JM. Paterson DL. Pasculle AW. Potoski BA Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infection Control & Hospital Epidemiology. 28(12):1382-8, 2007 Dec
Our residents our poised to achieve their professional goals. The following list includes former residents and their first post-PGY1 position.
Tiffany-Jade Kreys, PGY2 Psychiatry, Medical University of South Carolina
Van-Anh Le, PGY2 Solid Organ Transplant, University of Utah Hospitals and Clinics
Jay Martello, PGY2 Internal Medicine, West Virginia University Hospitals
Sarah Yost, PGY2 Solid Organ Transplant, Tampa General Hospital
Michael Armahizer, PGY2 Critical Care, UPMC Presbyterian
John Foley, Clinical Specialist, Hospital of the University of Pennsylvania
Christina Hedrick, Pharmacist, Waynesburg Hospital
David Johnson, PGY2 Solid Organ Transplant, UPMC Presbyterian
Matthew Felbinger, PGY2 Critical Care, Duke University Medical Center
Meredith Jernigan, PGY2 Infectious Diseases, UPMC Presbyterian
Gretchen Kipp, PGY2 Solid Organ Transplant, UPMC Presbyterian
Ibrahim Sales, PGY2 Ambulatory Care, UPMC Presbyterian
Maho Hibino, PGY2 Oncology, University of Washington Medical Center
Megan Kloet, PGY2 Critical Care, UPMC Presbyterian
Ian McGrane, PGY2 Psychiatry US Dept of Veterans Affairs, North Chicago
Stephanie Seaton, PGY2 Geriatrics, UPMC Presbyterian
Michael Smith, PGY2 Internal Medicine, UPMC Presbyterian
Kristin Bohnenberger, Fellowship Toxicology/Emergency Medicine, USVI-Florida Poison Information Center
Amanda Johnson, PGY2 Critical Care, PGY2 Pharmacy Management, UPMC Presbyterian
Vanessa Millisor, PGY2 Oncology, ST. Judes Children’s Research Hospital
Nicholas Schwier, PGY2 Cardiology, UPMC Presbyterian
Daniel Yarabinec, Clinical Specialist, Baylor Scott & While Health
Derek Bremmer, PGY2 Infectious Diseases, The Ohio State University Wexner Medical Center
Genevieve Hale, PGY2 Cardiology, VA Ann Arbor
Chelsea Harrison, PGY2 Ambulatory Care, Cleveland Clinic
Ashley Hedges, Patient Safety Fellowship, VA Pittsburgh
Alicia Lichvar, PGY2 Solid Organ Transplant, UPMC Presbyterian
Adam MacLasco, PGY2 Emergency Medicine, University of Illinois at Chicago
Erin Mathis, PGY2 Psychiatry, Middleton Memorial VA
Ryan Rivosecchi, PGY2 Critical Care, UPMC Presbyterian
Gwendolyn Lucy Wilkening, PGY2 Psychiatry, Western Psychiatric
Institute and Clinic of UPMC
Ayesha Ather, PGY2 Cardiology, University of Maryland
Maxwell Brown, PGY2 Oncology, UPMC Presbyterian/Shadyside
Emily Graham, PGY2 Oncology, Allegheny General Hospital
Cody Moore, Transplant Outcomes Fellowship, University of Pittsburgh School of Pharmacy
Anh Vu, PGY2 Solid Organ Transplant, UPMC Presbyterian
Cory Weaver, , PGY2 Critical Care, UPMC Presbyterian
Sherry Chen, PGY2 Cardiology, UPMC Presbyterian
Nicole Durie, PGY2 Cardiology, UPMC Presbyterian
Arlene Gao, PGY2 Oncology, UPMC Presbyterian/Shadyside
Carlo Iasella, Outcomes Research Fellowship, University of Pittsburgh School of Pharmacy
Kristen Knoph, PGY2 Pharmacotherapy, Mayo Clinic
Kyle Strnad, PGY2 Critical Care, UPMC Presbyterian
Moses Demehin, PGY2 Solid Organ Transplant, UPMC Presbyterian
Natalie Giron, PGY2 Oncology, University of Florida Cancer Center Orlando Health
Cassius Hudson, Jr., Pharmacist, James Cancer Center, OSU
Adrienne Szymkowiak, PGY2 Cardiology, UPMC Presbyterian
Hannah Welch, PGY2 Ambulatory Care – Global Health Track, UPMC Presbyterian
Ting Ting Wu